375 related articles for article (PubMed ID: 19272832)
21. Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques.
Vickers AA; Potter NJ; Fishwick CW; Chopra I; O'Neill AJ
J Antimicrob Chemother; 2009 Jun; 63(6):1112-7. PubMed ID: 19383727
[TBL] [Abstract][Full Text] [Related]
22. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF
Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552
[TBL] [Abstract][Full Text] [Related]
23. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.
Wyss PC; Gerber P; Hartman PG; Hubschwerlen C; Locher H; Marty HP; Stahl M
J Med Chem; 2003 Jun; 46(12):2304-12. PubMed ID: 12773035
[TBL] [Abstract][Full Text] [Related]
24. Dihydrofolate reductase as a therapeutic target.
Schweitzer BI; Dicker AP; Bertino JR
FASEB J; 1990 May; 4(8):2441-52. PubMed ID: 2185970
[TBL] [Abstract][Full Text] [Related]
25. Mutations leading to antifolate resistance in Chinese hamster ovary cells after exposure to the alkylating agent ethylmethanesulfonate.
Fanin R; Banerjee D; Volkenandt M; Waltham M; Li WW; Dicker AP; Schweitzer BI; Bertino JR
Mol Pharmacol; 1993 Jul; 44(1):13-21. PubMed ID: 8341268
[TBL] [Abstract][Full Text] [Related]
26. Active site-directed double mutants of dihydrofolate reductase.
Ercikan-Abali EA; Mineishi S; Tong Y; Nakahara S; Waltham MC; Banerjee D; Chen W; Sadelain M; Bertino JR
Cancer Res; 1996 Sep; 56(18):4142-5. PubMed ID: 8797582
[TBL] [Abstract][Full Text] [Related]
27. Basis for antifolate action and resistance in malaria.
Yuthavong Y
Microbes Infect; 2002 Feb; 4(2):175-82. PubMed ID: 11880049
[TBL] [Abstract][Full Text] [Related]
28. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase.
Volpato JP; Fossati E; Pelletier JN
J Mol Biol; 2007 Oct; 373(3):599-611. PubMed ID: 17868689
[TBL] [Abstract][Full Text] [Related]
29. In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.
Barrow EW; Dreier J; Reinelt S; Bourne PC; Barrow WW
Antimicrob Agents Chemother; 2007 Dec; 51(12):4447-52. PubMed ID: 17875993
[TBL] [Abstract][Full Text] [Related]
30. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
Sirichaiwat C; Intaraudom C; Kamchonwongpaisan S; Vanichtanankul J; Thebtaranonth Y; Yuthavong Y
J Med Chem; 2004 Jan; 47(2):345-54. PubMed ID: 14711307
[TBL] [Abstract][Full Text] [Related]
31. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance.
Rastelli G; Sirawaraporn W; Sompornpisut P; Vilaivan T; Kamchonwongpaisan S; Quarrell R; Lowe G; Thebtaranonth Y; Yuthavong Y
Bioorg Med Chem; 2000 May; 8(5):1117-28. PubMed ID: 10882022
[TBL] [Abstract][Full Text] [Related]
32. Plasmodium vivax dihydrofolate reductase point mutations from the Indian subcontinent.
Kaur S; Prajapati SK; Kalyanaraman K; Mohmmed A; Joshi H; Chauhan VS
Acta Trop; 2006 Feb; 97(2):174-80. PubMed ID: 16310156
[TBL] [Abstract][Full Text] [Related]
33. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
Bastien D; Ebert MC; Forge D; Toulouse J; Kadnikova N; Perron F; Mayence A; Huang TL; Vanden Eynde JJ; Pelletier JN
J Med Chem; 2012 Apr; 55(7):3182-92. PubMed ID: 22424148
[TBL] [Abstract][Full Text] [Related]
34. Emergence of an unusual sulfadoxine-pyrimethamine resistance pattern and a novel K540N mutation in dihydropteroate synthetase in Plasmodium falciparum isolates obtained from Car Nicobar Island, India, after the 2004 Tsunami.
Lumb V; Das MK; Mittra P; Ahmed A; Kumar M; Kaur P; Dash AP; Singh SS; Sharma YD
J Infect Dis; 2009 Apr; 199(7):1064-73. PubMed ID: 19220141
[TBL] [Abstract][Full Text] [Related]
35. Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
Pineda P; Kanter A; McIvor RS; Benkovic SJ; Rosowsky A; Wagner CR
J Med Chem; 2003 Jul; 46(14):2816-8. PubMed ID: 12825924
[TBL] [Abstract][Full Text] [Related]
36. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
Dias MV; Tyrakis P; Domingues RR; Paes Leme AF; Blundell TL
Structure; 2014 Jan; 22(1):94-103. PubMed ID: 24210757
[TBL] [Abstract][Full Text] [Related]
37. Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand.
Rungsihirunrat K; Sibley CH; Mungthin M; Na-Bangchang K
Am J Trop Med Hyg; 2008 Mar; 78(3):462-7. PubMed ID: 18337344
[TBL] [Abstract][Full Text] [Related]
38. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
Bowman AL; Lerner MG; Carlson HA
J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
[TBL] [Abstract][Full Text] [Related]
39. Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase.
Bennett BC; Xu H; Simmerman RF; Lee RE; Dealwis CG
J Med Chem; 2007 Sep; 50(18):4374-81. PubMed ID: 17696333
[TBL] [Abstract][Full Text] [Related]
40. Determinants of resistance to antifolates: biochemical phenotypes, their frequency of occurrence and circumvention.
Sirotnak FM
NCI Monogr; 1987; (5):27-35. PubMed ID: 2448655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
